AZN•benzinga•May 16, 2024 at 09:29 AM

AstraZeneca's High-level Results From SUPERNOVA Phase 3 Covid-19 Pre-exposure Prophylaxis Trial Showed Sipavibart (AZD3152) Reduced The Incidence Of Symptomatic Covid‑19 Vs. Control (Tixagevimab/Cilgavimab Or Placebo) In Immunocompromised Patients

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 16, 2024 by benzinga